DK0453898T3 - Use of TNF-specific antibodies as a drug in the treatment of ischemia and their consequences - Google Patents

Use of TNF-specific antibodies as a drug in the treatment of ischemia and their consequences

Info

Publication number
DK0453898T3
DK0453898T3 DK91105829.5T DK91105829T DK0453898T3 DK 0453898 T3 DK0453898 T3 DK 0453898T3 DK 91105829 T DK91105829 T DK 91105829T DK 0453898 T3 DK0453898 T3 DK 0453898T3
Authority
DK
Denmark
Prior art keywords
tnf
ischemia
consequences
drug
treatment
Prior art date
Application number
DK91105829.5T
Other languages
Danish (da)
Inventor
Peter Prof Dr Eckert
Matthias Dr Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0453898T3 publication Critical patent/DK0453898T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The use of anti-TNF antibodies to treat ischaemic and its sequelae, is claimed, especially when the ischaemia is an infarct or results from transplantation.
DK91105829.5T 1990-04-25 1991-04-12 Use of TNF-specific antibodies as a drug in the treatment of ischemia and their consequences DK0453898T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013114 1990-04-25
DE4037604A DE4037604A1 (en) 1990-04-25 1990-11-27 Use of anti-TNF antibodies to treat ischaemia and its sequelae - esp. to increase survival rate after myocardial infarct and transplants

Publications (1)

Publication Number Publication Date
DK0453898T3 true DK0453898T3 (en) 1995-10-09

Family

ID=25892502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91105829.5T DK0453898T3 (en) 1990-04-25 1991-04-12 Use of TNF-specific antibodies as a drug in the treatment of ischemia and their consequences

Country Status (7)

Country Link
EP (1) EP0453898B1 (en)
JP (1) JPH04364133A (en)
AT (1) ATE123226T1 (en)
DE (2) DE4037604A1 (en)
DK (1) DK0453898T3 (en)
ES (1) ES2073059T3 (en)
IL (1) IL97909A (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE4307508A1 (en) * 1993-03-10 1994-09-15 Knoll Ag Use of anti-TNF antibodies as a medicine in the treatment of heart failure (heart muscle weakness)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (en) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating tnfα-related disorders
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
JP2638652B2 (en) * 1988-07-18 1997-08-06 カイロン・コーポレーション Monoclonal antibody reacting with cachectin

Also Published As

Publication number Publication date
EP0453898A3 (en) 1991-12-18
ATE123226T1 (en) 1995-06-15
ES2073059T3 (en) 1995-08-01
DE59105609D1 (en) 1995-07-06
EP0453898A2 (en) 1991-10-30
IL97909A0 (en) 1992-06-21
JPH04364133A (en) 1992-12-16
IL97909A (en) 1997-09-30
EP0453898B1 (en) 1995-05-31
DE4037604A1 (en) 1991-10-31

Similar Documents

Publication Publication Date Title
DK0453898T3 (en) Use of TNF-specific antibodies as a drug in the treatment of ischemia and their consequences
ATE148130T1 (en) TYPE IV DIPEPTIDYL AMINOOPEPTIDASE INHIBITORS
DK0865293T3 (en) Blocking of T lymphocyte down-regulation associated with CTLA-4 signaling
ES2135062T3 (en) PIRAZOLO AND PYRROLOPYRIDINS.
DK0531370T3 (en) Inhibition of viral infection
NO963860L (en) Isoprenyl transferase inhibitors
ATE391512T1 (en) MODIFIED FACTOR VIII
DK0755249T3 (en) Use of Maillard reaction inhibitor to treat amyloidosis-based disease
ES2123156T3 (en) COMPOUNDS AND PROCEDURES FOR THE INHIBITION OF HIV AND SIMILAR VIRUSES.
DK1242119T3 (en) Combinations for the treatment of DNA viral infections comprising a loop diuretic and a cardiac glycoside
MX9203629A (en) MONOCLONAL ANTIBODIES COMPOSITIONS FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF BACTERIAL INFECTIONS DUE TO GROUP B STREPTOCOCCES.
DE68915453T2 (en) THERMOMECHANICAL TREATMENT OF FAST-SOLID AL-ALLOYS.
ATE235915T1 (en) TREATMENT OF HEMORRHAGIC VIRUS FEVER WITH PROTEIN C
DE60006412D1 (en) OXAZINOCHINOLONE FOR THE TREATMENT OF VIRAL INFECTIONS
EP0647138A4 (en) Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and dna sequences of the same.
DK0633928T3 (en) Microorganisms, their preparation and use
DK0656889T3 (en) 9-chloro-prostaglandin esters and amides and their use in the manufacture of drugs
DE60124791D1 (en) S-methyl-dihydro-ziprasidone for the treatment of psychiatric disorders.
FR2713657B1 (en) New vectors for the treatment of AIDS.
FI952018A (en) Use of BHAP in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection
DK1368478T3 (en) A polypeptide that induces HIV neutralizing antibodies
TW223019B (en)
DK0952982T3 (en) New Hepatitis B Inhibitors
IS4868A (en) Treatment of dementia-associated infections of the benign amide virus (HIV-1) with benzamide
MX9400210A (en) TREATMENT OF VIRAL INFECTIONS.